Alivus Life Sciences Limited (GLS)
Valuation Rating
Score: 14/100
Valuation Overview
| P/E Ratio | 31.496521 |
| P/B Ratio | 5.241338 |
| Dividend Yield | 3.7100002% |
| Current Price | ₹1086.0 |
| DCF Value | ₹372.9922089676339 |
| Upside Potential | N/A% |
Intrinsic Values
| Current Price | ₹1086.0 |
| DCF Value | ₹372.9922089676339 |
| Graham Value | ₹430.99999999999994 |
| DDM Value | ₹627.6428571428571 |
| Earnings Value | ₹552.6592671794222 |
| Average Value | ₹443.38367222056576 |
Growth Confidence
| Revenue Growth | 0% |
| Earnings Growth | 0% |
| Revenue Confidence | 0% |
| Earnings Confidence | 0% |
| Margin Confidence | 0% |
| Overall Growth Confidence | 0% |
Growth Metrics
| EPS Growth | -20.0% |
| Revenue Growth | -14.9% |
| Market Cap | ₹13324.89 Cr |
Valuation Analysis Score: 14/100
Undervaluation Score: 14/100
Valuation Score: 10/30
Growth Score: 4/30
Intrinsic Value Score: 0/40
Growth Score: 4/30
Intrinsic Value Score: 0/40
Key Analysis Points:
- Excellent operating margins above 20%
- Moderate growth confidence score above 40%
Recommendation
Caution - Stock may be overvalued, detailed analysis recommended
Detailed Metrics
Current Price: ₹1,086.00
Operating Margins: 23.5%
Revenue Growth: 0.0%
Earnings Growth: 0.0%
Growth Confidence: 52.5%
Risk Assessment Guide
- Score 80-100: Significantly undervalued with strong fundamentals
- Score 60-79: Moderately undervalued with good potential
- Score 40-59: Fairly valued with balanced metrics
- Score Below 40: Potentially overvalued, exercise caution
Last Updated: 2025-01-23 06:44:07